Showing 4941-4950 of 10417 results for "".
- International Women's Day: Botox Cosmetic, IFundWomen Partner for Grant Programhttps://practicaldermatology.com/news/international-womens-day-botox-cosmetic-ifundwomen-for-grant-program/2461596/In honor of International Women's Day, Allergan Aesthetics,’ an AbbVie company, is partnering with IFundWomen, the funding marketplace for women-owned businesses, on a grant program. Women entrepreneurs can apply for the opportunity to receive one of 20 grants worth
- Leo Pharma's Adtralza Gets Nod or Adults with AD in Japanhttps://practicaldermatology.com/news/leo-pharmas-adtralza-gets-nod-or-adults-with-ad-in-japan/2461476/The Japan Ministry of Health, Labor and Welfare has granted approval for the manufacturing and marketing of LEO Pharma’s Adtralza (tralokinumab) subcutaneous injection for adults with atopic dermatitis, which has inadequately responded to conventional therapies. “Today&
- EMA Accepts Filing of MAA for Almirall's Lebrikizumab in ADhttps://practicaldermatology.com/news/ema-accepts-filing-of-maa-for-almiralls-lebrikizumab-in-ad/2461408/The European Medicines Agency (EMA) has accepted the filing of the Marketing Authorization Application (MAA) for Almirall’s lebrikizumab for the treatment of moderate to severe atopic dermatitis. Lebrikizumab is a novel, investigational, monoclonal antibod
- Apyx Medical Corporation Receives FDA 510(k) Clearance for Renuvion Handpiecehttps://practicaldermatology.com/news/apyx-medical-corporation-receives-fda-510k-clearance-for-renuvion-handpiece/2461216/The U.S. Food and Drug Administration has granted marketing clearance to Apyx Medical Corporation’s Renuvion Dermal Handpiece for specific dermal resurfacing procedures. The Renuvion Dermal Handpiece is indicated for dermatological procedures for the treatment of moderate to
- Happy 25th Birthday Restylane!https://practicaldermatology.com/news/happy-25th-birthday-restylane/2460928/Galderma’s Restylane is celebrating 25 years on the market. Since launching in Europe in 1996, Restylane has celebrated many milestones across the globe. This includes the first approval for use by the U.S. Food and Drug Administration (FDA) in 2003 and in China by the
- Industry Veteran Ann Deren-Lewis Joins Mindera as Chief Commercial Officerhttps://practicaldermatology.com/news/industry-veteran-ann-deren-lewis-joins-mindera-as-chief-commercial-officer/2460879/Ann Deren-Lewis is Mindera’s new Chief Commercial Officer. She most recently served as Sr. Vice President of Corporate Development at Zerigo Health (formerly Clarify Medical) where she led commercial operations, including sales, marketing, medical affairs, and the clinical c
- Aerolase Appoints Industry Vet Didier Leclercq to Leadership Teamhttps://practicaldermatology.com/news/aerolase-appoints-industry-vet-didier-leclercq-to-leadership-team/2460448/Didier Leclercq is Aerolase’s new Vice President of Global Market Development. Prior to his role as Managing Director of the SHIELD innovation center of Nestlé Skin Health/Galderma, Mr. Leclercq ran Q-Med once it was acquired by G
- Regenerative Medicine Business News: Bimini Acquires Healeonhttps://practicaldermatology.com/news/regenerative-medicine-business-news-bimini-acquires-healeon/2460432/Bimini Health Tech has acquired Healeon Medical, Inc., a company that designs, develops, manufactures, and markets medical devices for autologous, point-of-care treatments. Healeon's products include: the signature HD PRP system which fe
- Todd Wood Named DermTech's New Chief Commercial Officerhttps://practicaldermatology.com/news/todd-wood-named-dermtechs-new-chief-commercial-officer/2459883/Todd Wood is DermTech’s new Chief Commercial Officer. Mr. Wood will oversee the Sales and Marketing functions. With 25 years of pharmaceutical and medical device commercialization experience, Mr. Wood has launched multiple market leading product
- Amgevita, Amgen's Biosimilar Adalimumab, Launches in Europehttps://practicaldermatology.com/news/amgevita-amgens-biosimilar-adalimumab-launches-in-europe/2457555/Amgen's Amgevita, a biosimilar to adalimumab, has launched in markets across Europe. Amgevita is the first adalimumab biosimilar to be approved by the European Commission (EC) and is authorized for the treatment of inflammatory diseases in adults, including moder